@article{TCR30099,
author = {Nityam Rathi and Benjamin L. Maughan and Neeraj Agarwal and Umang Swami},
title = {The tango of immunotherapy and targeted therapy in metastatic renal cell carcinoma},
journal = {Translational Cancer Research},
volume = {8},
number = {8},
year = {2019},
keywords = {},
abstract = {Over the past decade, the mortality rate due to advanced renal cell carcinoma (RCC) has seen a significant decline (1). This has been accomplished mostly due to the rapid transformation of the treatment landscape of advanced clear cell RCC (ccRCC) which comprises 70% to 80% of RCC (2). Therapies targeting vascular endothelial growth factor pathway, mammalian target of rapamycin pathway, and immune checkpoints have replaced interferon-α and high dose interleukin-2 in clinical practice (2). Despite of these advancements, many patients do not benefit from many of these recent drug approvals. The attrition rate of patients from first line to second-line therapy is very high at 50%, and only approximately 25% patients remain alive to allow treatment in the third line therapy setting (3). This has pushed the momentum to bring the most effective therapies to the first-line setting to improve outcomes. One recent strategy to achieve this has been to combine targeted therapies with immunotherapies.},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/30099}
}